Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells

Yoko S. Kaneko, Takeshi Takayanagi, Hiroshi Nagasaki, Yu Kodani, Akira Nakashima, Keiji Mori, Atsushi Suzuki, Mitsuyasu Itoh, Kazunao Kondo, Toshiharu Nagatsu, Miyuki Ota, Akira Ota

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We previously showed that aripiprazole increases intracellular NADPH and glucose-6-phosphate dehydrogenase mRNA in PC12 cells. Aripiprazole presumably activates a system that concurrently detoxifies reactive oxygen species and replenishes NADPH. Nrf2, a master transcriptional regulator of redox homeostasis genes, also activates the pentose phosphate pathway, including NADPH production. Therefore, our aim was to determine whether aripiprazole activates Nrf2 in PC12 cells. Aripiprazole increased mRNA expression of Nrf2-dependent genes (NAD(P)H–quinone oxidoreductase-1, Nqo1; heme oxygenase-1, HO1; and glutamate-cysteine ligase catalytic subunit) and protein expression of Nqo1 and HO1 in these cells (p < 0.05). To maintain increased Nrf2 activity, it is necessary to inhibit Nrf2 degradation; this is done by causing Nrf2 to dissociate from Keap1 or β-TrCP. However, in aripiprazole-treated cells, the relative amount of Nrf2 anchored to Keap1 or β-TrCP was unaffected and Nrf2 in the nuclear fraction decreased (p < 0.05). Aripiprazole did not affect phosphorylation of Nrf2 at Ser40 and decreased the relative amount of acetylated Nrf2 (p < 0.05). The increase in Nqo1 and HO1 in aripiprazole-treated cells cannot be explained by the canonical Nrf2-degrading pathways. Further experiments are needed to determine the biochemical mechanisms underlying the aripiprazole-induced increase in these enzymes.

Original languageEnglish
Pages (from-to)757-772
Number of pages16
JournalJournal of Neural Transmission
Volume122
Issue number6
DOIs
Publication statusPublished - 01-06-2015

Fingerprint

Heme Oxygenase-1
PC12 Cells
NAD
Oxidoreductases
NADP
Glutamate-Cysteine Ligase
Pentose Phosphate Pathway
Messenger RNA
Aripiprazole
Glucosephosphate Dehydrogenase
Genes
Oxidation-Reduction
Reactive Oxygen Species
Catalytic Domain
Homeostasis
Phosphorylation
Enzymes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kaneko, Yoko S. ; Takayanagi, Takeshi ; Nagasaki, Hiroshi ; Kodani, Yu ; Nakashima, Akira ; Mori, Keiji ; Suzuki, Atsushi ; Itoh, Mitsuyasu ; Kondo, Kazunao ; Nagatsu, Toshiharu ; Ota, Miyuki ; Ota, Akira. / Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells. In: Journal of Neural Transmission. 2015 ; Vol. 122, No. 6. pp. 757-772.
@article{c98c3ceeb13a408a8294cad2cab4f35f,
title = "Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells",
abstract = "We previously showed that aripiprazole increases intracellular NADPH and glucose-6-phosphate dehydrogenase mRNA in PC12 cells. Aripiprazole presumably activates a system that concurrently detoxifies reactive oxygen species and replenishes NADPH. Nrf2, a master transcriptional regulator of redox homeostasis genes, also activates the pentose phosphate pathway, including NADPH production. Therefore, our aim was to determine whether aripiprazole activates Nrf2 in PC12 cells. Aripiprazole increased mRNA expression of Nrf2-dependent genes (NAD(P)H–quinone oxidoreductase-1, Nqo1; heme oxygenase-1, HO1; and glutamate-cysteine ligase catalytic subunit) and protein expression of Nqo1 and HO1 in these cells (p < 0.05). To maintain increased Nrf2 activity, it is necessary to inhibit Nrf2 degradation; this is done by causing Nrf2 to dissociate from Keap1 or β-TrCP. However, in aripiprazole-treated cells, the relative amount of Nrf2 anchored to Keap1 or β-TrCP was unaffected and Nrf2 in the nuclear fraction decreased (p < 0.05). Aripiprazole did not affect phosphorylation of Nrf2 at Ser40 and decreased the relative amount of acetylated Nrf2 (p < 0.05). The increase in Nqo1 and HO1 in aripiprazole-treated cells cannot be explained by the canonical Nrf2-degrading pathways. Further experiments are needed to determine the biochemical mechanisms underlying the aripiprazole-induced increase in these enzymes.",
author = "Kaneko, {Yoko S.} and Takeshi Takayanagi and Hiroshi Nagasaki and Yu Kodani and Akira Nakashima and Keiji Mori and Atsushi Suzuki and Mitsuyasu Itoh and Kazunao Kondo and Toshiharu Nagatsu and Miyuki Ota and Akira Ota",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s00702-014-1350-8",
language = "English",
volume = "122",
pages = "757--772",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "6",

}

Kaneko, YS, Takayanagi, T, Nagasaki, H, Kodani, Y, Nakashima, A, Mori, K, Suzuki, A, Itoh, M, Kondo, K, Nagatsu, T, Ota, M & Ota, A 2015, 'Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells', Journal of Neural Transmission, vol. 122, no. 6, pp. 757-772. https://doi.org/10.1007/s00702-014-1350-8

Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells. / Kaneko, Yoko S.; Takayanagi, Takeshi; Nagasaki, Hiroshi; Kodani, Yu; Nakashima, Akira; Mori, Keiji; Suzuki, Atsushi; Itoh, Mitsuyasu; Kondo, Kazunao; Nagatsu, Toshiharu; Ota, Miyuki; Ota, Akira.

In: Journal of Neural Transmission, Vol. 122, No. 6, 01.06.2015, p. 757-772.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aripiprazole increases NAD(P)H–quinone oxidoreductase-1 and heme oxygenase-1 in PC12 cells

AU - Kaneko, Yoko S.

AU - Takayanagi, Takeshi

AU - Nagasaki, Hiroshi

AU - Kodani, Yu

AU - Nakashima, Akira

AU - Mori, Keiji

AU - Suzuki, Atsushi

AU - Itoh, Mitsuyasu

AU - Kondo, Kazunao

AU - Nagatsu, Toshiharu

AU - Ota, Miyuki

AU - Ota, Akira

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We previously showed that aripiprazole increases intracellular NADPH and glucose-6-phosphate dehydrogenase mRNA in PC12 cells. Aripiprazole presumably activates a system that concurrently detoxifies reactive oxygen species and replenishes NADPH. Nrf2, a master transcriptional regulator of redox homeostasis genes, also activates the pentose phosphate pathway, including NADPH production. Therefore, our aim was to determine whether aripiprazole activates Nrf2 in PC12 cells. Aripiprazole increased mRNA expression of Nrf2-dependent genes (NAD(P)H–quinone oxidoreductase-1, Nqo1; heme oxygenase-1, HO1; and glutamate-cysteine ligase catalytic subunit) and protein expression of Nqo1 and HO1 in these cells (p < 0.05). To maintain increased Nrf2 activity, it is necessary to inhibit Nrf2 degradation; this is done by causing Nrf2 to dissociate from Keap1 or β-TrCP. However, in aripiprazole-treated cells, the relative amount of Nrf2 anchored to Keap1 or β-TrCP was unaffected and Nrf2 in the nuclear fraction decreased (p < 0.05). Aripiprazole did not affect phosphorylation of Nrf2 at Ser40 and decreased the relative amount of acetylated Nrf2 (p < 0.05). The increase in Nqo1 and HO1 in aripiprazole-treated cells cannot be explained by the canonical Nrf2-degrading pathways. Further experiments are needed to determine the biochemical mechanisms underlying the aripiprazole-induced increase in these enzymes.

AB - We previously showed that aripiprazole increases intracellular NADPH and glucose-6-phosphate dehydrogenase mRNA in PC12 cells. Aripiprazole presumably activates a system that concurrently detoxifies reactive oxygen species and replenishes NADPH. Nrf2, a master transcriptional regulator of redox homeostasis genes, also activates the pentose phosphate pathway, including NADPH production. Therefore, our aim was to determine whether aripiprazole activates Nrf2 in PC12 cells. Aripiprazole increased mRNA expression of Nrf2-dependent genes (NAD(P)H–quinone oxidoreductase-1, Nqo1; heme oxygenase-1, HO1; and glutamate-cysteine ligase catalytic subunit) and protein expression of Nqo1 and HO1 in these cells (p < 0.05). To maintain increased Nrf2 activity, it is necessary to inhibit Nrf2 degradation; this is done by causing Nrf2 to dissociate from Keap1 or β-TrCP. However, in aripiprazole-treated cells, the relative amount of Nrf2 anchored to Keap1 or β-TrCP was unaffected and Nrf2 in the nuclear fraction decreased (p < 0.05). Aripiprazole did not affect phosphorylation of Nrf2 at Ser40 and decreased the relative amount of acetylated Nrf2 (p < 0.05). The increase in Nqo1 and HO1 in aripiprazole-treated cells cannot be explained by the canonical Nrf2-degrading pathways. Further experiments are needed to determine the biochemical mechanisms underlying the aripiprazole-induced increase in these enzymes.

UR - http://www.scopus.com/inward/record.url?scp=84930195564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930195564&partnerID=8YFLogxK

U2 - 10.1007/s00702-014-1350-8

DO - 10.1007/s00702-014-1350-8

M3 - Article

C2 - 25504008

AN - SCOPUS:84930195564

VL - 122

SP - 757

EP - 772

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 6

ER -